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Age-related macular degeneration (AMD) is the most com-
mon cause of irreversible visual loss in the western world and
constitutes one of the main socioeconomical health issues
worldwide. AMD is a complex multifactorial disease with an
uncertain etiology associatedwith genetic and environmental
risk factors. The majority of patients present with a slowly
developing “dry” atrophic form of AMD, but about 10% of
patients will develop a rapidly progressing “wet” form with
choroidal neovascular membrane.
This issue on AMD compiles 8 exciting manuscripts
that include meticulously performed reviews of the currently
available literature and original clinical and experimental
studies.
It is well-believed that the incidence of AMD and its
progression to advanced stagesmay be reduced by controlling
modifiable environmental risk factors. As a result, several
groups have studied the effects of several interventions in
clinical practice.
Among them, cigarette smoking is a proven risk factor for
AMD. The S. Velilla et al. review summarizes the epidemi-
ological studies evaluating the association between smoking
and AMD, the mechanisms through which smoking induces
damage to the chorioretinal tissues, and the relevance of
advising patients to quit smoking for their visual health.
Micronutrient supplementation enhances antioxidant
defense and healthy eyes and might prevent or retard AMD.
The role of nutritional supplements on AMD prevention
is addressed in two manuscripts. M. D. Pinazo-Dura´n et
al. review the proposed pathogenic mechanisms of AMD,
as well as the role of antioxidants and omega 3 fatty acids
supplements in AMD prevention.This paper is accompanied
by X. Xu et al.’s paper that explores the protective effects
of Fructus lycii ethanol extract and its active components
lutein/zeaxanthin in vitro and in vivo AMDmice model.
P. Ferna´ndez-Robredo et al. review the evolution of AMD
treatment and the limitations of the current therapies as well
as the socioeconomic impact of AMD. There is currently
no cure available for AMD, and even palliative treatments
are rare. Treatment options show several side effects, are of
high cost, and only treat the consequence, not the cause of
the pathology. For this reason, many options involving cell
therapy mainly based on retinal and iris pigment epithelium
cells as well as stem cells are being tested. Moreover, tissue
engineering strategies to design andmanufacture scaffolds to
mimic Bruch’s membrane are very diverse and under inves-
tigation. Both alternative therapies are aimed at preventing
and/or curing AMD and are reviewed herein.
The establishment of future retinal pigment epithelium
(RPE) replacement therapy is partly dependent on the
availability of tissue-engineered RPE cells, which may be
enhanced by the development of suitable storage methods
for RPE. L. Pasovic et al. show in their article that the
preservation of RPE cells is critically dependent on storage
temperature.
Rheopheresis is an apparently safe and effective form
of membrane differential filtration for the elimination of
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high molecular weight proteins. J. Studnicˇka et al.’s paper
deals with those aspects showing that rheopheresis reduced
drusenoid pigment epithelium detachment, improved the
electroretinographic function of photoreceptors, and pre-
vented the decline of visual acuity.
Treatment of neovascular AMD is further reviewed in
two papers. K. Fang et al. identify the predictors of visual
response to the bevacizumab treatment of neovascular AMD
in a multicenter trial including 144 participants from the
NATTB study. Baseline VA and genotype of rs10490924 were
both important predictors for visual response to bevacizumab
at 6 months. Finally, R. Casaroli-Marano et al. conducted
an observational retrospective multicenter study of the man-
agement of patients with neovascular AMD. Achieving the
visual outcomes reported in pivotal trials, early diagnosis, a
proactive approach (more treating than follow-up visits), and
close monitoring might be the key to successfully manage
neovascular AMD.
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